CN111481605A - 一种预防糖尿病足的浴足液及其制备方法和应用 - Google Patents
一种预防糖尿病足的浴足液及其制备方法和应用 Download PDFInfo
- Publication number
- CN111481605A CN111481605A CN202010405970.5A CN202010405970A CN111481605A CN 111481605 A CN111481605 A CN 111481605A CN 202010405970 A CN202010405970 A CN 202010405970A CN 111481605 A CN111481605 A CN 111481605A
- Authority
- CN
- China
- Prior art keywords
- silver
- sodium alginate
- bath liquid
- foot bath
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 43
- 208000008960 Diabetic foot Diseases 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000661 sodium alginate Substances 0.000 claims abstract description 51
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 51
- 210000002683 foot Anatomy 0.000 claims abstract description 50
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 48
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000004366 Glucose oxidase Substances 0.000 claims abstract description 24
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 24
- 108010015776 Glucose oxidase Proteins 0.000 claims abstract description 23
- 229940116332 glucose oxidase Drugs 0.000 claims abstract description 23
- 235000019420 glucose oxidase Nutrition 0.000 claims abstract description 23
- 229910052751 metal Inorganic materials 0.000 claims abstract description 22
- 239000002184 metal Substances 0.000 claims abstract description 22
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 19
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 19
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 19
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 19
- 235000006533 astragalus Nutrition 0.000 claims abstract description 19
- 244000170916 Paeonia officinalis Species 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 241001061264 Astragalus Species 0.000 claims abstract description 14
- 210000004233 talus Anatomy 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 6
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 5
- 241000207929 Scutellaria Species 0.000 claims abstract description 5
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 31
- 238000000605 extraction Methods 0.000 claims description 26
- 241000723353 Chrysanthemum Species 0.000 claims description 18
- 241000245665 Taraxacum Species 0.000 claims description 18
- -1 silver ion compound Chemical class 0.000 claims description 16
- 241000037740 Coptis chinensis Species 0.000 claims description 14
- 241000218176 Corydalis Species 0.000 claims description 13
- 241000612118 Samolus valerandi Species 0.000 claims description 13
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 13
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 claims description 5
- 229910000367 silver sulfate Inorganic materials 0.000 claims description 5
- 241000218202 Coptis Species 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 4
- 244000137773 Viola philippica Species 0.000 claims description 3
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 claims description 3
- 229940019931 silver phosphate Drugs 0.000 claims description 3
- 229910000161 silver phosphate Inorganic materials 0.000 claims description 3
- KIIUTKAWYISOAM-UHFFFAOYSA-N silver sodium Chemical compound [Na].[Ag] KIIUTKAWYISOAM-UHFFFAOYSA-N 0.000 claims description 3
- 241001106477 Paeoniaceae Species 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 230000008961 swelling Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 208000002193 Pain Diseases 0.000 abstract description 2
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 241000628997 Flos Species 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000009636 Huang Qi Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 244000001632 Acorus gramineus Species 0.000 description 2
- 235000013073 Acorus gramineus Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 244000042430 Rhodiola rosea Species 0.000 description 2
- 235000003713 Rhodiola rosea Nutrition 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 244000235659 Rubus idaeus Species 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000405217 Viola <butterfly> Species 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 241000208682 Liquidambar Species 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 208000005268 Neurogenic Arthropathy Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029326 Neuropathic arthropathy Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004935 right thumb Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Abstract
本发明提供了一种预防糖尿病足的浴足液及其制备方法和应用,属于中医药领域。本发明中所用的原料价格便宜,能够长期使用,其中蒲公英、地丁、菊花、双花和赤芍共同作用,能够补气清肺、收涩止血、益智养心、散瘀消肿、活血、去湿的作用;生黄芪、黄芩和黄连,构成“三黄”,利水、退肿、生肌,具有清热解毒,抗炎消肿,活血化瘀、止痛收敛,引入到糖尿病足治疗与保养中,能够在实现制剂的药物促渗以及功能实现方面起到更好的效果;金属酞菁、纳米银海藻酸钠复合物、葡萄糖氧化酶和β‑D‑葡萄糖协同作用,具有抗菌止痒的作用,葡萄糖氧化酶可催化β‑D‑葡萄糖和水反应,再在金属酞菁的作用下产生了杀菌消炎的作用,具有很高的活性。
Description
技术领域
本发明涉及中医药技术领域,尤其涉及一种预防糖尿病足的浴足液及其制备方法和应用。
背景技术
糖尿病患者因周围神经病变与外周血管疾病合并过高的机械压力,可引起足部软组织及骨关节系统的破坏与畸形形成,进而引发一系列足部问题,从轻度的神经症状到严重的溃疡、感染、血管疾病、Charcot关节病和神经病变性骨折。如果积极治疗不能充分解决下肢出现的症状和并发症,则会造成灾难性的后果。因此,在糖尿病患者中开展对足部问题的早期预防和治疗将有重要的意义。
现有技术中关于治疗糖尿病足的药物有很多,如CN201010590112.9公开了依据糖尿病足患者病程长短及出现的不同症状,提供分期治疗糖尿病足的药方,针对糖尿病足早期、中期和晚期的不同,使用不同的治疗中药组合物,但是针对的是糖尿病足发病后的治疗,存在存在不能预防的效果,CN201710184112.0公开了预防糖尿病足的浴足液,以红景天、石菖蒲、覆盆子、香兰素、螺旋藻、大果木姜子、木贼和枫香脂制备浴足液,使用的红景天、石菖蒲和覆盆子价格昂贵,不适合于广泛应用。
发明内容
有鉴于此,本发明的目的在于提供一种预防糖尿病足的浴足液及其制备方法和应用。本发明提供的浴足液原料价格便宜,且能够实现糖尿病足的预防,预料效果良好。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种预防糖尿病足的浴足液,包括以下重量百分含量的原料:
5~10%蒲公英、2~5%地丁、2~5%菊花、5~10%双花、1~2%赤芍、2~4%金属酞菁、5~10%纳米银海藻酸钠复合物、10~15%生黄芪、5~10%黄芩、5~10%黄连、0.1~0.15%葡萄糖氧化酶、5~10%β-D-葡萄糖和余量的水。
优选地,所述浴足液包括以下重量百分含量的原料:
10%蒲公英、5%地丁、5%菊花、10%双花、2%赤芍、4%金属酞菁、10%纳米银海藻酸钠复合物、15%生黄芪、10%黄芩、10%黄连、0.15%葡萄糖氧化酶、10%β-D-葡萄糖和余量的水。
优选地,所述浴足液包括以下重量百分含量的原料:
8%蒲公英、4%地丁、4%菊花、8%双花、1%赤芍、4%金属酞菁、10%纳米银海藻酸钠复合物、10%生黄芪、5%黄芩、5%黄连、0.1%葡萄糖氧化酶、5%β-D-葡萄糖和余量的水。
优选地,所述纳米银海藻酸钠复合物中纳米银与海藻酸钠的质量比为2~5:1。
本发明还提供了上述技术方案所述浴足液的制备方法,包括以下步骤:
将蒲公英、地丁、菊花、双花、赤芍和水进行第一提取,得到第一提取液;
将生黄芪、黄芩、黄连和水进行第二提取,得到第二提取液;
将所述第一提取液、第二提取液、金属酞菁、纳米银海藻酸钠复合物、葡萄糖氧化酶和β-D-葡萄糖混合,得到所述浴足液。
优选地,所述第一提取的温度为70~80℃,所述第一提取的时间为2~4h。
优选地,所述第二提取的温度为90~100℃,所述第二提取的时间为2~4h。
优选地,所述纳米银海藻酸钠复合物由包括以下步骤的方法制备得到:
将银离子化合物溶于海藻酸钠水溶液中,加入还原剂得到所述纳米银海藻酸钠复合物。
优选地,所述银离子化合物包括硝酸银、硫酸银或磷酸银。
本发明还提供了上述技术方案所述浴足液在制备预防糖尿病足药物中的应用。
本发明提供了一种预防糖尿病足的浴足液,包括以下重量百分含量的原料:5~10%蒲公英、2~5%地丁、2~5%菊花、5~10%双花、1~2%赤芍、2~4%金属酞菁、5~10%纳米银海藻酸钠复合物、10~15%生黄芪、5~10%黄芩、5~10%黄连、0.1~0.15%葡萄糖氧化酶、5~10%β-D-葡萄糖和余量的水。本发明中所用的原料价格便宜,能够长期使用,其中蒲公英、地丁、菊花、双花和赤芍共同作用,能够补气清肺、收涩止血、益智养心、散瘀消肿、活血、去湿的作用;生黄芪、黄芩和黄连,构成“三黄”,利水、退肿、生肌,具有清热解毒,抗炎消肿,具有活血化瘀、止痛收敛、抗菌消炎的作用,引入到糖尿病足治疗与保养中,能够在实现制剂的药物促渗以及功能实现方面起到更好的效果;金属酞菁、纳米银海藻酸钠复合物、葡萄糖氧化酶和β-D-葡萄糖协同作用,具有抗菌止痒的作用,葡萄糖氧化酶可催化β-D-葡萄糖和水反应,再在金属酞菁的作用下产生了杀菌消炎的作用,具有很高的活性,对微生物有很强的亲和性,很容易被通常呈负电性的各类细菌、真菌、病毒所吸附,快速全面地渗入到细菌细胞内,使细胞内的蛋白质凝固变性从而抑制细菌的分裂繁殖功能,纳米银通过破坏细菌细胞壁,与细菌细胞内的酶和蛋白质等重要物质相互作用,影响细菌的能力传递,并与细菌细胞内的DNA相互作用,影响细菌细胞分裂,最终导致细菌死亡。
具体实施方式
本发明提供了一种预防糖尿病足的浴足液,包括以下重量百分含量的原料:
5~10%蒲公英、2~5%地丁、2~5%菊花、5~10%双花、1~2%赤芍、2~4%金属酞菁、5~10%纳米银海藻酸钠复合物、10~15%生黄芪、5~10%黄芩、5~10%黄连、0.1~0.15%葡萄糖氧化酶、5~10%β-D-葡萄糖和余量的水。
在本发明中,所述浴足液优选包括以下重量百分含量的原料:
10%蒲公英、5%地丁、5%菊花、10%双花、2%赤芍、4%金属酞菁、10%纳米银海藻酸钠复合物、15%生黄芪、10%黄芩、10%黄连、0.15%葡萄糖氧化酶、10%β-D-葡萄糖和余量的水。
在本发明中,所述浴足液优选包括以下重量百分含量的原料:
8%蒲公英、4%地丁、4%菊花、8%双花、1%赤芍、4%金属酞菁、10%纳米银海藻酸钠复合物、10%生黄芪、5%黄芩、5%黄连、0.1%葡萄糖氧化酶、5%β-D-葡萄糖和余量的水。
在本发明中,所述纳米银海藻酸钠复合物中纳米银与海藻酸钠的质量比优选为2~5:1。
本发明还提供了上述技术方案所述浴足液的制备方法,包括以下步骤:
将蒲公英、地丁、菊花、双花、赤芍和水进行第一提取,得到第一提取液;
将生黄芪、黄芩、黄连和水进行第二提取,得到第二提取液;
将所述第一提取液、第二提取液、金属酞菁、纳米银海藻酸钠复合物、葡萄糖氧化酶和β-D-葡萄糖混合,得到所述浴足液。
本发明将蒲公英、地丁、菊花、双花、赤芍和水进行第一提取,得到第一提取液。在本发明中,所述第一提取的温度优选为70~80℃,所述第一提取的时间优选为2~4h。
本发明将生黄芪、黄芩、黄连和水进行第二提取,得到第二提取液。在本发明中,所述第二提取的温度优选为90~100℃,所述第二提取的时间优选为2~4h。
本发明将所述第一提取液、第二提取液、金属酞菁、纳米银海藻酸钠复合物、葡萄糖氧化酶和β-D-葡萄糖混合,得到所述浴足液。在本发明中,所述纳米银海藻酸钠复合物优选由包括以下步骤的方法制备得到:
将银离子化合物溶于海藻酸钠水溶液中,加入还原剂得到所述纳米银海藻酸钠复合物。
在本发明中,所述银离子化合物优选包括硝酸银、硫酸银或磷酸银。
本发明对所述还原剂的种类和用量没有特殊的限定,能够使银离子化合物还原得到纳米银即可。
本发明还提供了上述技术方案所述浴足液在制备预防糖尿病足药物中的应用。
为了进一步说明本发明,下面结合实例对本发明提供的预防糖尿病足的浴足液及其制备方法和应用进行详细地描述,但不能将它们理解为对本发明保护范围的限定。
实施例1
浴足液包括以下重量百分含量的原料:
10%蒲公英、5%地丁、5%菊花、10%双花、2%赤芍、4%金属酞菁、10%纳米银海藻酸钠复合物、15%生黄芪、10%黄芩、10%黄连、0.15%葡萄糖氧化酶、10%β-D-葡萄糖和余量的水,纳米银海藻酸钠复合物中纳米银与海藻酸钠的质量比为2:1。
浴足液的制备方法,包括以下步骤:
将蒲公英、地丁、菊花、双花、赤芍和水进行第一提取(温度为70℃,时间为4h),得到第一提取液;
将生黄芪、黄芩、黄连和水进行第二提取(温度为90℃,时间为4h),得到第二提取液;
将所述第一提取液、第二提取液、金属酞菁、纳米银海藻酸钠复合物、葡萄糖氧化酶和β-D-葡萄糖混合,得到所述浴足液。
其中纳米银海藻酸钠复合物由包括以下步骤的方法制备得到:
将硝酸银溶于海藻酸钠水溶液中,加入硼氢化钠得到纳米银海藻酸钠复合物。
实施例2
浴足液包括以下重量百分含量的原料:
8%蒲公英、4%地丁、4%菊花、8%双花、1%赤芍、4%金属酞菁、10%纳米银海藻酸钠复合物、10%生黄芪、5%黄芩、5%黄连、0.1%葡萄糖氧化酶、5%β-D-葡萄糖和余量的水,纳米银海藻酸钠复合物中纳米银与海藻酸钠的质量比为5:1。
浴足液的制备方法,包括以下步骤:
将蒲公英、地丁、菊花、双花、赤芍和水进行第一提取(温度为80℃,时间为2h),得到第一提取液;
将生黄芪、黄芩、黄连和水进行第二提取(温度为100℃,时间为2h),得到第二提取液;
将所述第一提取液、第二提取液、金属酞菁、纳米银海藻酸钠复合物、葡萄糖氧化酶和β-D-葡萄糖混合,得到所述浴足液。
其中纳米银海藻酸钠复合物由包括以下步骤的方法制备得到:
将硫酸银溶于海藻酸钠水溶液中,加入维生素C得到纳米银海藻酸钠复合物。
实施例3
5%蒲公英、2%地丁、2%菊花、5%双花、1%赤芍、2%金属酞菁、5%纳米银海藻酸钠复合物、10%生黄芪、5%黄芩、5%黄连、0.1%葡萄糖氧化酶、5%β-D-葡萄糖和余量的水,纳米银海藻酸钠复合物中纳米银与海藻酸钠的质量比为3:1。
浴足液的制备方法,包括以下步骤:
将蒲公英、地丁、菊花、双花、赤芍和水进行第一提取(温度为70℃,时间为2h),得到第一提取液;
将生黄芪、黄芩、黄连和水进行第二提取(温度为100℃,时间为4h),得到第二提取液;
将所述第一提取液、第二提取液、金属酞菁、纳米银海藻酸钠复合物、葡萄糖氧化酶和β-D-葡萄糖混合,得到所述浴足液。
其中纳米银海藻酸钠复合物由包括以下步骤的方法制备得到:
将硫酸银溶于海藻酸钠水溶液中,加入柠檬酸钠得到纳米银海藻酸钠复合物。
对照组
使用清水代替浴足液
实施例1~3以及对照组的治疗效果
病历1:张某,女,60岁。Ⅱ型糖尿病6年,近1年常感下肢麻木发凉,时有肌肉痉挛,并触觉降低,右足拇指出现青黑现象,诊断为:糖尿病足,使用本发明实施例1的浴足液泡脚,连续使用15天,脚趾青黑恢复正常,能够正常步行。
病例2:李某,女,50岁。Ⅱ型糖尿病4年,近半年下肢麻木发凉,触觉降低,诊断为:糖尿病足,使用清水泡脚,糖尿病足症状加重,时有肌肉痉挛,部分脚趾出现青黑现象。
病例3:某糖尿病足早期患者,有5年病史,表现为下肢末梢神经病变,患足出现虫蚁感或踏棉感,使用本发明实施例2的浴足液泡脚,连续使用5天,诸症得到明显缓解,基本消除虫蚁感或踏棉感。
病例4:某糖尿病足早期患者,有3年病史,表现为下肢皮温降低、疼痛、间歇性跛行,使用本发明实施例3的浴足液泡脚,连续使用15天,诸症得到明显缓解,可正常行走。
以上所述仅是本发明的优选实施方式,并非对本发明作任何形式上的限制。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种预防糖尿病足的浴足液,其特征在于,包括以下重量百分含量的原料:
5~10%蒲公英、2~5%地丁、2~5%菊花、5~10%双花、1~2%赤芍、2~4%金属酞菁、5~10%纳米银海藻酸钠复合物、10~15%生黄芪、5~10%黄芩、5~10%黄连、0.1~0.15%葡萄糖氧化酶、5~10%β-D-葡萄糖和余量的水。
2.根据权利要求1所述的浴足液,其特征在于,所述浴足液包括以下重量百分含量的原料:
10%蒲公英、5%地丁、5%菊花、10%双花、2%赤芍、4%金属酞菁、10%纳米银海藻酸钠复合物、15%生黄芪、10%黄芩、10%黄连、0.15%葡萄糖氧化酶、10%β-D-葡萄糖和余量的水。
3.根据权利要求1所述的浴足液,其特征在于,所述浴足液包括以下重量百分含量的原料:
8%蒲公英、4%地丁、4%菊花、8%双花、1%赤芍、4%金属酞菁、10%纳米银海藻酸钠复合物、10%生黄芪、5%黄芩、5%黄连、0.1%葡萄糖氧化酶、5%β-D-葡萄糖和余量的水。
4.根据权利要求1~3任一项所述的浴足液,其特征在于,所述纳米银海藻酸钠复合物中纳米银与海藻酸钠的质量比为2~5:1。
5.权利要求1~4任一项所述浴足液的制备方法,其特征在于,包括以下步骤:
将蒲公英、地丁、菊花、双花、赤芍和水进行第一提取,得到第一提取液;
将生黄芪、黄芩、黄连和水进行第二提取,得到第二提取液;
将所述第一提取液、第二提取液、金属酞菁、纳米银海藻酸钠复合物、葡萄糖氧化酶和β-D-葡萄糖混合,得到所述浴足液。
6.根据权利要求5所述的制备方法,其特征在于,所述第一提取的温度为70~80℃,所述第一提取的时间为2~4h。
7.根据权利要求5所述的制备方法,其特征在于,所述第二提取的温度为90~100℃,所述第二提取的时间为2~4h。
8.根据权利要求5所述的制备方法,其特征在于,所述纳米银海藻酸钠复合物由包括以下步骤的方法制备得到:
将银离子化合物溶于海藻酸钠水溶液中,加入还原剂得到所述纳米银海藻酸钠复合物。
9.根据权利要求8所述的制备方法,其特征在于,所述银离子化合物包括硝酸银、硫酸银或磷酸银。
10.权利要求1~4任一项所述浴足液在制备预防糖尿病足药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010405970.5A CN111481605A (zh) | 2020-05-14 | 2020-05-14 | 一种预防糖尿病足的浴足液及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010405970.5A CN111481605A (zh) | 2020-05-14 | 2020-05-14 | 一种预防糖尿病足的浴足液及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111481605A true CN111481605A (zh) | 2020-08-04 |
Family
ID=71790747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010405970.5A Pending CN111481605A (zh) | 2020-05-14 | 2020-05-14 | 一种预防糖尿病足的浴足液及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111481605A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115006582A (zh) * | 2022-07-18 | 2022-09-06 | 南通大学 | 一种抗炎抗氧化纳米敷料及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103041438A (zh) * | 2012-12-31 | 2013-04-17 | 钟春燕 | 一种治疗糖尿病足溃疡的湿性抗菌水凝胶敷料 |
CN104906563A (zh) * | 2015-06-25 | 2015-09-16 | 浙江理工大学 | 一种抗菌止痒组合物及其制剂 |
CN105012546A (zh) * | 2014-04-26 | 2015-11-04 | 陈庆华 | 一种治疗糖尿病足的三黄足浴包及其使用方法 |
CN107753951A (zh) * | 2017-07-19 | 2018-03-06 | 青岛海芬健康产业科技有限公司 | 一种含蒲地蓝治疗糖尿病足的浴足液 |
-
2020
- 2020-05-14 CN CN202010405970.5A patent/CN111481605A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103041438A (zh) * | 2012-12-31 | 2013-04-17 | 钟春燕 | 一种治疗糖尿病足溃疡的湿性抗菌水凝胶敷料 |
CN105012546A (zh) * | 2014-04-26 | 2015-11-04 | 陈庆华 | 一种治疗糖尿病足的三黄足浴包及其使用方法 |
CN104906563A (zh) * | 2015-06-25 | 2015-09-16 | 浙江理工大学 | 一种抗菌止痒组合物及其制剂 |
CN107753951A (zh) * | 2017-07-19 | 2018-03-06 | 青岛海芬健康产业科技有限公司 | 一种含蒲地蓝治疗糖尿病足的浴足液 |
Non-Patent Citations (1)
Title |
---|
王志敏等: "中药制剂治疗糖尿病足2例", 《人民军医》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115006582A (zh) * | 2022-07-18 | 2022-09-06 | 南通大学 | 一种抗炎抗氧化纳米敷料及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101195008B (zh) | 一种治疗妇科疾病的黄蒲洁肤洗剂及其制备工艺 | |
CN101095736A (zh) | 一种治疗急慢性咽炎、扁桃体炎的中药组合物及其制备方法 | |
CN111481605A (zh) | 一种预防糖尿病足的浴足液及其制备方法和应用 | |
CN113209238A (zh) | 治疗靶向药物引起的手足综合症的洗剂及其制备方法 | |
CN104189128A (zh) | 治疗糖尿病周围神经病变的中药熏洗剂 | |
CN115671220A (zh) | 一种治疗阴虚湿热型便秘的中药组合物 | |
CN1173726C (zh) | 一种治疗恶性肿瘤病的药物及其制备方法 | |
CN108635389A (zh) | 一种治疗2型糖尿病的中药配方及其冲剂的制备方法 | |
CN112138084B (zh) | 一种治疗支气管扩张症气阴两虚、痰热壅肺证的中药组合物及其应用 | |
CN1127344C (zh) | 一种治疗糖尿病及其并发症的口服丸剂 | |
CN101732425B (zh) | 一种牛皮癣外用药组合物 | |
CN106511770B (zh) | 一种治疗带状疱疹的中药制剂及其制备方法 | |
CN101554438B (zh) | 治疗痔疮的中药 | |
CN1285367C (zh) | 一种治疗糖尿病的药物制剂及其制备方法 | |
CN111514237B (zh) | 一种治疗病毒性心肌炎的中药组合物及其制备方法 | |
CN109331152A (zh) | 一种治疗脉管炎的中药组合物 | |
CN116920047B (zh) | 一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法 | |
CN1297309C (zh) | 关节痹络通外用药组合物及其制备方法 | |
CN116509935B (zh) | 一种治疗糖尿病周围神经病变的中药组合物及其应用 | |
CN112206279B (zh) | 一种治疗室性心律失常的中药组合物及其制备方法和应用 | |
CN105456555B (zh) | 一种中药组合物在制备治疗糖尿病足药物中的应用 | |
CN105106764A (zh) | 一种用于治疗妊娠呕吐的药物制剂 | |
CN118320000A (zh) | 一种具有解毒凉血功效的中药组合物、解毒凉血合剂及其制备方法和应用 | |
CN1586526A (zh) | 一种治疗结核病的复方药物及其制备方法 | |
CN115887590A (zh) | 一种治疗银屑病的蒙药药浴组合物、其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200804 |